SN 2310

Drug Profile

SN 2310

Alternative Names: SN 2310 Injectable Emulsion; SN2310; TOCOSOL Camptothecin

Latest Information Update: 20 Apr 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sonus Pharmaceuticals
  • Developer OncoGenex Pharmaceuticals
  • Class Antineoplastics; Camptothecins
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 30 Mar 2011 Discontinued - Phase-I for Solid tumours in USA (IV)
  • 10 Nov 2008 OncoGenex Pharmaceuticals completes enrolment in its phase1 trial for solid tumours in USA
  • 21 Aug 2008 OncoGenex Technologies has merged with Sonus Pharmaceuticals to form OncoGenex Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top